Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bemcentinib + decitabine
- Development stage
- Unknown
- Lead developer
- Oncoinvent Solutions
- Modality
- Small Molecules
- Administration
- Oral (bemcentinib), Intravenous (decitabine)
01
Overview
Bemcentinib + decitabine is a combination therapy composed of bemcentinib, an oral, highly selective small molecule inhibitor of the receptor tyrosine kinase AXL, and decitabine, a DNA methyltransferase inhibitor classified as a hypomethylating agent. Bemcentinib blocks AXL signaling, which is associated with proliferation, survival, resistance to chemotherapy, and immunosuppression in acute myeloid leukemia (AML). Decitabine inhibits DNA methylation, reactivating silenced genes and promoting differentiation or apoptosis of leukemic cells. The combination is under investigation for treating AML in patients unsuitable for intensive chemotherapy, with clinical studies showing safety, tolerability, and anti-leukemic activity, particularly in previously untreated and relapsed/refractory AML unfit for standard induction therapy[1][3][5].
- Other names
- bemcentinib + decitabine
02
Targets
AXL (AXL receptor tyrosine kinase)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on bemcentinib + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bemcentinib + decitabine.